GET DAILY SIGNALSNeumora Therapeutics (NMRA): Analyst Targets Average $6.30 After Pipeline Reset
Key Takeaways
- The central $6.30 stock price target is the arithmetic mean of six verified, current analyst price targets for Neumora Therapeutics, Inc. (NMRA), a clinical-stage neuroscience biopharmaceutical company.
- That mean of $6.33 is far above the latest verified price of roughly $0.37, implying an upside of more than 1,500% — a very large move.
- Individual analyst targets span a wide range, from a low of $3 (Stifel) to a high of $14 (Guggenheim), reflecting deep disagreement about the value of the early-stage pipeline.
- The targets were sharply reset after Neumora's lead depression drug, navacaprant, failed all three Phase 3 KOASTAL studies, prompting its discontinuation and a 35% workforce reduction.
- Bullish analysts point to NMRA-511 (Alzheimer's disease agitation), NMRA-898 (schizophrenia), and NMRA-215 (obesity), plus an extended cash runway into the third quarter of 2027.
- The biggest risks are binary clinical readouts, a micro-cap valuation, limited near-term revenue, and the possibility of further dilution.
- For more detail on this ticker's developments, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
The $6.30 central target is a calculated average, not an officially published consensus. It is the arithmetic mean of six verifiable analyst price targets: H.C. Wainwright at $7 (reiterated August 24, 2026), Mizuho at $4 (August 17, 2026), Needham at $5 (August 14, 2026), RBC Capital at $5 (August 14, 2026), Stifel at $3 (May 12, 2026), and Guggenheim at $14 (May 8, 2026). The mean works out to about $6.33, rounded to $6.30, with a low-to-high range of $3 to $14.
Data providers show a broad spread depending on how many analysts they count — from roughly $5.25 to about $6.57 — but the underlying individual targets are the source here. Views diverge sharply. Most firms maintain Buy or Outperform ratings, but Stifel sits at Hold with a $3 target, and J.P. Morgan carries a Sell rating without a published target. Guggenheim's $14 target is a notable outlier, while the rest cluster between $3 and $7.
The reasoning has shifted entirely after the KOASTAL failures. Needham's Ami Fadia cut the firm's target to $5 from $8 while removing navacaprant revenue and costs from the model, and RBC's Brian Abrahams lowered the target to $5 from $7. Bulls frame the pipeline as optionality on Alzheimer's agitation and schizophrenia, while bears argue the remaining assets are too early-stage to justify a meaningful premium. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Neumora shares closed near $0.37 in late October 2026, giving the company a market capitalization around $69 million. Reaching $6.30 would require a gain of roughly 1,600% — a very large move by any standard, and a reversal of a punishing downtrend that took the stock from a 52-week high of $3.65 in February 2026 to a low near $0.32.
The path to a higher valuation runs almost entirely through clinical execution. With no marketed products, Neumora's value rests on data from NMRA-511 in Alzheimer's disease agitation, NMRA-898 in schizophrenia, and NMRA-215 in obesity. Management extended the cash runway into the third quarter of 2027 through the 35% workforce cut, which generates about $10 million in annualized savings. Until these programs generate positive data, the shares are likely to remain hostage to sentiment and cash concerns.
What Could Support a Move Toward the Target
- Pipeline optionality: NMRA-511, a V1a receptor antagonist for Alzheimer's agitation, is expected to advance toward a Phase 2b study; positive Phase 1 data for NMRA-898 (an M4 positive allosteric modulator) in schizophrenia could re-rate the stock.
- Cost discipline: The restructuring extends the cash runway into Q3 2027, reducing near-term dilution risk while the company reaches several clinical milestones.
- Valuation reset: At a roughly $69 million market cap, even modest clinical progress can produce outsized percentage moves in a micro-cap with several catalysts on the calendar.
What Could Prevent the Target From Being Reached
- Clinical risk: The KOASTAL-1, -2, and -3 failures show how quickly a lead program can collapse; the remaining pipeline is earlier-stage and unproven.
- Funding and dilution: A pre-revenue company with a runway into late 2027 may still need to raise capital, which can dilute existing shareholders.
- Concentration risk: With no diversified revenue base, the investment case hinges on a handful of single-trial readouts that carry binary outcomes.
- Wide analyst disagreement: The $3-to-$14 spread signals low confidence in any single valuation and reflects genuine uncertainty about what the pipeline is worth.
Technical Levels and Market Structure
The chart shows a persistent long-term downtrend. The 52-week low near $0.32, set in mid-October 2026, is the most important support level; a break below it would signal renewed selling pressure. On the upside, the $0.50 area and the $1.00 psychological level mark early resistance zones, while the prior high of $3.65 sits far above the current price. Given the scale of the required move, technical levels matter less than clinical catalysts in shaping the stock's direction.
Time Horizon and What Investors Should Monitor
Analyst targets typically reflect a roughly 12-month research horizon, though firms do not always state this explicitly and horizons can vary. The most important upcoming items are clinical: Phase 1 data for NMRA-898 in schizophrenia, advancement of NMRA-511 toward a Phase 2b Alzheimer's agitation study, and updates on NMRA-215. Investors should also watch the next quarterly earnings report, expected in November 2026, for updated cash guidance, and any analyst revisions or target changes that follow new clinical data or financing activity.
Using AI Tools in My Research Process
I often turn to Tickeron's AI Daily Buy/Sell Signals when monitoring volatile names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For a catalyst-driven micro-cap, it helps flag momentum changes more quickly than manual review alone, though it serves only as one input alongside independent analysis of clinical updates and financials.
Final Assessment
The question of whether Neumora Therapeutics can reach $6.30 is, in effect, a question about whether its early-stage pipeline can deliver. The $6.30 figure is the average of six analyst targets spanning $3 to $14, and it sits roughly 1,600% above the current price — a very large move that would require successful clinical readouts, renewed investor confidence, and a materially higher valuation for a pre-revenue company. Bulls see hidden optionality in the Alzheimer's, schizophrenia, and obesity programs; bears see binary risk, a short runway, and little to justify a premium after three Phase 3 failures. With the next major data readouts approaching, the target remains an analyst-derived benchmark rather than a forecast, and the outcome will depend on data that has not yet been reported. From what I see, this remains a high-risk setup best suited for those comfortable with binary outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NMRA in +33.65% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NMRA advanced for three days, in 146 of 167 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NMRA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Moving Average Convergence Divergence (MACD) for NMRA just turned positive on October 08, 2026. Looking at past instances where NMRA's MACD turned positive, the stock continued to rise in 16 of 20 cases over the following month. The odds of a continued upward trend are 80%.
NMRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 35 cases where NMRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NMRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for NMRA entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.554) is normal, around the industry mean (2.974). P/E Ratio (-0.299) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. NMRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NMRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement